Merck & Co.
213 E Grand Avenue, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA 02141
United States
4223 articles about Merck & Co.
-
The market opportunity for pulmonary arterial hypertension drugs stretches well beyond the 500–1,000 Americans diagnosed with the disease each year—and biopharma is taking note.
-
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
8/3/2023
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
-
Both public and private programs aim to help veterans apply their skills in the biotech and pharmaceutical sector.
-
Merck Announces Second-Quarter 2023 Financial Results
8/1/2023
Merck, known as MSD outside the United States and Canada, announced financial results for the second quarter of 2023.
-
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
7/28/2023
Merck announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
-
Two late-stage trial wins for Merck’s V116 investigational pneumococcal vaccine could make it a serious challenger to Pfizer’s Prevnar 20 in the space.
-
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
7/27/2023
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals.
-
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
7/26/2023
Merck, known as MSD outside of the United States and Canada, and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk melanoma.
-
The Phase III trial, which will test the companies' mRNA-based personalized cancer vaccine and Merck’s blockbuster Keytruda checkpoint inhibitor, is slated for completion by the fall of 2029.
-
Merck is Safeguarding the Environment Through Green Chemistry
7/25/2023
Many of us are trying to go green, changing our behavior and lifestyles to reduce our impact on the environment.
-
Merck Announces Fourth-Quarter 2023 Dividend
7/25/2023
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share of the company’s common stock for the fourth quarter of 2023.
-
Merck Receives Positive European Union CHMP Opinion for Gefapixant
7/21/2023
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, developed for the treatment for adults with refractory or unexplained chronic cough.
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction
7/21/2023
Opinion granted based on positive progression-free survival results from the Phase 3 KEYNOTE-811 trial.
-
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
7/19/2023
Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy met one of its primary endpoints of progression-free survival as treatment for newly diagnosed patients with high-risk locally advanced cervical cancer.
-
Late-stage study suggests Merck’s Keytruda is a promising treatment candidate in newly diagnosed patients with locally advanced cervical cancer, inducing better progression-free survival.
-
J&J, Merck and Pfizer are the subjects of a House Judiciary Committee investigation for their alleged participation in a government-sanctioned censorship campaign during the COVID-19 pandemic.
-
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck
7/18/2023
Illumina Inc., a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, announced the five founding members of the Alliance for Genomic Discovery.
-
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program
7/17/2023
BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System, announced receipt of the grand prize award in the 2023 Merck Advance Biotech Grant Program.
-
This week: Cancer license deals from J&J and BeiGene, a potential $7B acquisition by Roche and confirmed $1.9B Lilly buy, EU fine for Illumina, and more legal challenges to the Inflation Reduction Act
-
Following its initial lawsuit last month, Merck has now requested that a federal judge rule on its Inflation Reduction Act case against the Biden administration without a trial.